Prostate cancer in Black men: what the data actually says

The figures below come from primary sources fetched for this article. Each line carries its source.

• Black men are diagnosed with prostate cancer at a rate of roughly 200 per 100,000 men per year, compared to about 122 per 100,000 for white men, a 64 percent higher incidence rate. (NCI SEER Cancer Statistics, 2019-2023 data)
• Black men die from prostate cancer at a rate of 36.2 per 100,000 per year, compared to 18.1 per 100,000 for white men. That is a mortality rate roughly double that of white men. (NCI SEER Cancer Statistics, 2020-2024 data)
• 1 in 6 Black men will develop prostate cancer in his lifetime, compared to 1 in 8 white men. 1 in 35 Black men will die from it. (Prostate Cancer Foundation, Additional Facts for Black Men; ACS Cancer Statistics for African American and Black People, 2025)
• Prostate cancer is the most commonly diagnosed cancer among Black men, accounting for an estimated 44 percent of all new cancer diagnoses in Black men. In 2025, approximately 57,330 new cases were estimated among Black men, with 6,150 estimated deaths. (ACS Cancer Statistics for African American and Black People, 2025)
• Black men tend to be diagnosed at a younger age and are more likely to have more aggressive disease at diagnosis compared to white men. (CDC, Prostate Cancer Risk Factors)
• Research indicates that when Black men receive treatment within equal-access systems such as the Veterans Health Administration, they show equivalent or better prostate cancer-specific survival, suggesting that a large part of the mortality disparity reflects unequal access to high-quality care, not biology alone. (ACS Cancer Statistics for African American and Black People, 2025)

Two tests are used to screen for prostate cancer in men who have no symptoms.

PSA test. A blood draw measures the level of prostate-specific antigen, a protein produced by the prostate. Elevated PSA can signal cancer, but it can also reflect benign prostate enlargement, infection, or recent physical activity. A single elevated result does not mean cancer; it typically triggers a follow-up test or secondary evaluation before any biopsy is considered.

Digital rectal exam (DRE). A clinician manually feels the prostate through the rectal wall to check for lumps or irregularities. The DRE is sometimes performed alongside PSA testing, though the US Preventive Services Task Force does not recommend it as a standalone screening tool due to limited evidence for it alone. (CDC, Prostate Cancer Screening)

Neither test is perfect. PSA can be elevated for reasons other than cancer, and some prostate cancers produce normal PSA levels. Screening catches cancer earlier, which for aggressive disease is genuinely life-saving. It also catches slow-growing cancers that may never cause harm, which can lead to treatment and its side effects that were never necessary. The medical community calls this overdiagnosis and overtreatment. How you weigh that tradeoff is a personal decision made with your doctor.

This is where the major organizations diverge, and that divergence matters for Black men specifically.

American Cancer Society (ACS): Recommends that Black men, classified as high-risk, have an opportunity to make an informed decision with their health care provider about whether to be screened starting at age 45. Men with more than one first-degree relative diagnosed with prostate cancer at an early age (under 65) should begin that conversation at age 40. (ACS, Early Detection of Prostate Cancer)

American Urological Association (AUA), 2023 guideline (amended 2026): For individuals with Black ancestry, germline mutations, or a strong family history, the AUA recommends offering prostate cancer screening beginning at ages 40 to 45 (Strong Recommendation). (AUA, Early Detection of Prostate Cancer Guideline)

Prostate Cancer Foundation (PCF), 2023 guidelines published in NEJM Evidence: A 19-member expert panel recommends a baseline PSA test for Black men between ages 40 and 45, with annual screening strongly considered for those who elect it. (PCF, Prostate Cancer Foundation Highlights Evidence-Based Prostate Cancer Screening Guidelines for Black Men)

US Preventive Services Task Force (USPSTF), 2018 recommendation (update in progress as of 2026): For men aged 55-69, the USPSTF gives a Grade C recommendation: the decision to screen should be an individual one, made after discussing potential benefits and harms with a clinician. For men 70 and older, the USPSTF recommends against routine PSA screening (Grade D). An update to this recommendation is currently in progress. (USPSTF, Prostate Cancer Screening)

The practical bottom line: The ACS, AUA, and PCF all agree that Black men should start the screening conversation earlier than the general population, at age 40 to 45. No major organization recommends routine screening after age 70, and men with less than a 10-year life expectancy are generally not offered screening.

PSA screening reduces deaths from prostate cancer in some men. It also produces false positives that trigger unnecessary biopsies, and it finds some cancers that grow so slowly they would never cause harm in a man's lifetime. The treatment for those slow-growing cancers, whether surgery or radiation, carries real risks: urinary incontinence, erectile dysfunction, bowel problems. This is the core tension.

For Black men, the math looks different. Research published in NEJM Evidence found that the harm-to-benefit ratio of PSA screening is more favorable for Black men than for the general population, because prostate cancer in Black men is on average more aggressive and occurs at younger ages. The number of Black men who need to be screened to prevent one death is lower than the general population figure. (NEJM Evidence, Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men)

That does not mean screening is without risk for Black men. Overdiagnosis and overtreatment are real possibilities for anyone. Current clinical practice mitigates some of that risk through secondary biomarker testing, MRI before biopsy, and active surveillance for low-risk disease found on screening.

The ACS, AUA, and PCF frame this as shared decision-making: a conversation between you and a clinician where your values, your family history, your risk tolerance, and your health status all factor in. That conversation works best when you initiate it, because many primary care providers do not raise it proactively.

Treatment decisions depend on the stage, grade, and aggressiveness of the cancer, as well as your age and overall health. The major options are:

Active surveillance. For low-risk, slow-growing cancers, many men choose to monitor rather than treat immediately. This means regular PSA tests, periodic biopsies, and in some cases MRI. Rates of active surveillance for low-risk prostate cancer more than doubled between 2014 and 2021, reaching nearly 60 percent of men diagnosed with low-risk disease. Active surveillance is not the same as doing nothing; it is a deliberate, monitored approach that defers treatment unless the cancer shows signs of progression. (NCI, Prostate Cancer Treatment PDQ)

Surgery (radical prostatectomy). The prostate gland is removed, along with surrounding tissue. The procedure can be performed as open surgery, laparoscopically, or with robotic assistance. When cancer is confined to the prostate, surgery can be curative. Risks include urinary incontinence and erectile dysfunction, which vary in severity and duration by patient and surgical team experience. (Memorial Sloan Kettering Cancer Center, Prostate Cancer Treatment)

Radiation therapy. External beam radiation directs high-energy beams at the tumor from outside the body, typically over several weeks. Brachytherapy places small radioactive seeds directly inside the prostate. Newer techniques including stereotactic body radiation therapy (SBRT) deliver higher doses in fewer sessions. (NCI, Prostate Cancer Treatment PDQ)

Hormone therapy (androgen deprivation therapy, or ADT). Prostate cancer is typically driven by testosterone. ADT reduces testosterone levels through medication (LHRH agonists, LHRH antagonists) or, less commonly, surgical removal of the testicles. It is often used in combination with radiation for higher-risk disease, or for disease that has spread beyond the prostate. (NCI, Prostate Cancer Treatment PDQ)

Focal therapy. For select patients with small tumors confined to one part of the prostate, minimally invasive focal therapies such as high-intensity focused ultrasound (HIFU) or cryotherapy may be options. They are available at specialized centers and are not yet standard of care in the same way surgery and radiation are. (Memorial Sloan Kettering Cancer Center, Prostate Cancer Treatment)

Advanced and metastatic disease. For cancer that has spread beyond the prostate, treatment typically combines hormone therapy with newer androgen receptor inhibitors (enzalutamide, apalutamide) or abiraterone acetate. Chemotherapy, PARP inhibitors for specific genetic mutations (particularly BRCA2), radium-223 for bone metastases, and PSMA-targeted therapies are additional options depending on disease characteristics. (NCI, Prostate Cancer Treatment PDQ)

The right treatment is not universal. Two men with the same PSA level and the same cancer grade may make different choices based on age, other health conditions, and what side effects they are willing to accept.

• A Black urologist or primary-care provider. Research consistently shows that concordance between patient and provider race can improve communication and trust. Our provider directory lets you search for Black physicians near you.
• The Black men's health hub. Our Black men's health hub brings together condition guides, provider resources, and community context specific to Black men's health.
• Patient resources from the Prostate Cancer Foundation. PCF offers a free downloadable guide, "Additional Facts for Black Men and Their Families," a risk assessment tool, and a provider locator at pcf.org. Their helpline is 1.800.757.CURE (2873).
• If you do not have a regular doctor or insurance. Community health centers funded under Section 330 of the Public Health Service Act provide sliding-scale primary care regardless of ability to pay. Find one through findahealthcenter.hrsa.gov. The CDC's cancer screening resources page (cdc.gov/prostate-cancer/resources) lists additional support options.

Bring this list. You do not need to memorize the research. You need to start the conversation.

1. Given that I am a Black man, at what age should I start discussing prostate cancer screening, and what does that discussion involve?
2. What is my PSA level today, and what does it mean relative to my age?
3. If my PSA is elevated, what is the next step, and does that automatically mean a biopsy?
4. My [father / brother / uncle] had prostate cancer at [age]. How does that family history change my risk and the recommended starting age?
5. If I decide to be screened and something is found, what are the realistic treatment options, and what are the side effects I should understand before deciding?
6. What is active surveillance, and who is it appropriate for?
7. How often should we revisit this conversation as I get older?

1. American Cancer Society - Cancer Statistics for African American and Black People, 2025. pressroom.cancer.org
2. PubMed Central / ACS - "Cancer statistics for African American and Black people, 2025," CA: A Cancer Journal for Clinicians. pmc.ncbi.nlm.nih.gov/articles/PMC11929131/
3. National Cancer Institute, SEER Program - Prostate Cancer Stat Facts. seer.cancer.gov/statfacts/html/prost.html
4. American Cancer Society - Prostate Cancer Early Detection Guideline. cancer.org
5. US Preventive Services Task Force - Prostate Cancer Screening Recommendation. uspreventiveservicestaskforce.org
6. American Urological Association - Early Detection of Prostate Cancer Guideline, 2023. auanet.org
7. Prostate Cancer Foundation - PCF Highlights Evidence-Based Prostate Cancer Screening Guidelines for Black Men. pcf.org
8. Prostate Cancer Foundation - Additional Facts for Black Men and Their Families. pcf.org
9. CDC - Prostate Cancer Risk Factors. cdc.gov/prostate-cancer/risk-factors/
10. CDC - Prostate Cancer Screening. cdc.gov/prostate-cancer/screening/index.html
11. NCI - Prostate Cancer Treatment PDQ (patient version). cancer.gov
12. Memorial Sloan Kettering Cancer Center - Prostate Cancer Treatment options overview. mskcc.org
13. NEJM Evidence - "Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men." evidence.nejm.org